Gastroenterologie up2date, Table of Contents Gastroenterologie up2date 2025; 21(01): 10-12DOI: 10.1055/a-2461-0433 Wichtige Studien im Fokus Kommentar zu „Anti-TL1A bei Colitis ulcerosa effektiv“ Peter Hasselblatt Recommend Article Abstract Buy Article All articles of this category Comment on: Anti-TL1A bei Colitis ulcerosa effektivGastroenterologie up2date 2025; 21(01): 10-10DOI: 10.1055/a-2504-5091 Full Text References Literatur 1 Bamias G, Menghini P, Pizarro TT. et al. Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD. Gut 2024; 2 Solitano V, Estevinho MM, Ungaro F. et al. TL1A Inhibition in Inflammatory Bowel Disease: A Pipeline Review. BioDrugs 2025; 3 Danese S, Klopocka M, Scherl EJ. et al. Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study. Clin Gastroenterol Hepatol 2021; 19: 2324-2332.e6 4 Sands BE, Feagan BG, Peyrin-Biroulet L. et al. Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis. N Engl J Med 2024; 391: 1119-1129
